Smaragda

The Global HPV Communication website, a digital platform that serves as a one-stop-shop for your HPV vaccine communication needs. This web portal provides a variety of Communication for Development (C4D) resources on the HPV vaccine, including tools, campaign examples, how-to-guides, fact sheets, adaptable messages, and more. Resources are available for a variety of target audiences, including program implementers, health workers, government officials, teachers and educators, journalists, media professionals, and more.

In Germany there was a court decision of the Bundesgerichtshof and later a law: Patienten­rechte­gesetz 2013 § 630e BGB (https://www.gesetze-im-internet.de/bgb/__630e.html), which stated that it was mandatory to share information regarding vaccines and vaccine safety before routine vaccination and defined the content of these information. The RKI displays the information in a format of FAQs.

Building the capacity to improve vaccine acceptance and uptake through the curation of evidence based resources. CANVax makes it easier for public health professionals to find and collect resources to inform their work in improving vaccine acceptance and uptake.

Whether you are a government regulator, a scientist, or a health care provider, the Vaccine Safety Quarterly has relevant vaccine safety information for you. It is a newsletter for our friends, partners, and members. It highlights opinions from the world’s leading vaccine safety experts, gives you a description of new projects and stories and opinions from our members and reports on our work’s impact. It will help you stay informed and offer ways to get involved.

This database offers a current, nationwide overview of existing information materials and offers on the subject of vaccination from various providers. Commercial materials were excluded - as far as recognizable. You have the options to search for keywords or for example languages, to select for certain standard vaccinations according to age or diseases, to search for special materials for parents, doctors or other multipliers or specifically for brochures, films, radio contributions, etc.

Dengue fever is present in Asia, the Pacific, the Caribbean, the Americas and Africa. Humans are infected with dengue virus through bites of tiger (Aedes) mosquitoes. There are 4 different dengue types, and infection with one type gives little immune protection against the other types. After an incubation of 8-10 days, a mild and usually self-limited flu-like illness develops. Current scientific evidence shows that sequential infection increases the risk of a severe form of the infection with bleedings - dengue hemorrhagic fever. In several Asian countries, dengue hemorrhagic fever has become an important cause of disease and death, mainly in children. No specific treatment or vaccine exists for dengue, and general intensive care is often needed.

The relations between vaccine hesitancy (VH) and individual socioeconomic status (SES) vary with context and remain poorly understood. We examined associations between parental SES and VH levels and their potential mediation by two attitudinal factors: commitment to making “good” health-related decisions and trust in mainstream medicine. Vaccine refusal and delay are frequent among French parents, especially the more educated. Our results suggest that levels of commitment and trust play a key role in shaping VH. Suitable educational interventions are needed to restore trust in authorities and vaccines. Helping healthcare professionals to communicate better with vaccine-hesitant parents is also essential.

AusVaxSafety is a national system for monitoring vaccine safety in Australia. The first annual report from AusVaxSafety summarises information from parents and carers who responded to an SMS about their child's health a few days after receiving a vaccine at routine National Immunisation Program schedule points in 2016-17. The report includes infographics providing a visual representation of the information collected through those responses, including the number of parents and carers who responded and health information about their children. A separate infographic summarises responses from parents and carers of Aboriginal and Torres Strait Islander children, who receive additional vaccines at the 12 and 18 month schedule points. The results confirm that vaccines in the National Immunisation Program are safe.

Presenter: Sharon G. Humiston, MD, MPH September 2018

Presented by: the Society of Obstetricians and Gynaecologists of Canada Date: 28 March 2018 Speaker: Dr. Vanessa Poliquin

Extensive section providing information to help parents to decide whether to immunize their child with the measles-maps-rubella (MMR) vaccine. It comprises an Introduction; a section dedicated to symptoms of the three diseases; 3 FAQs regarding the vaccine, its safety and the impact of MMR vaccination; comparisons of the risks for each of the diseases; a section helping making a decision and sections FOR and for NOT vaccinating the child. Moreover links to access organizations for and against the vaccination are provided and finally a table is given so that the parent decides what to do. Finally additional references are provided for more information.

MMR decision aid and Dealing with requests for vaccination exemption

A fact sheet about how vaccines are shown to be safe, noting how all vaccines are carefully tested.

INFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS VARICELLA ZOSTER VIRUS VACCINE